Press Releases

GENESIS Pharma, a leading regional biopharma company focused on the commercialization of innovative medicines in Europe, today announced the expansion of its longstanding commercial partnership with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), the leading RNAi therapeutics company. The extended agreement broadens the geographical reach of the collaboration to include four Nordic markets -Denmark, Finland, Norway, and Sweden- alongside the thirteen markets in Southeast Europe already within the scope of the partnership. GENESIS Pharma shall commercialize a portfolio of RNAi therapeutics for serious cardiomyopathy conditions and rare genetic diseases across this expanded territory.

Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of quizartinib in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML).

GENESIS Pharma, a regional biopharma company focused on the commercialization of innovative medicines in Central and Eastern Europe, announces an exclusive agreement with Otsuka Pharmaceutical Europe Ltd. (OPEL), the European operation of global healthcare company Otsuka Pharmaceutical Co., Ltd., for donidalorsen. Under the terms of the agreement, GENESIS Pharma will exclusively distribute and commercialize donidalorsen in fourteen markets: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia.

GENESIS Pharma, a regional biopharma company focused on the commercialization of innovative medicines in Central and Eastern Europe, announces an exclusive agreement with Krystal Biotech, Inc. (NASDAQ: KRYS), a fully-integrated, global biotechnology company specializing in genetic medicines, for the distribution and commercialization of beremagene geperpavec-svdt, a redosable genetic medicine and the first corrective therapy for the treatment of dystrophic epidermolysis bullosa (DEB), in twelve markets in Central and Eastern Europe.

GENESIS Pharma has been awarded the DIAMOND highest distinction for its performance in sustainable development for 2024-2025, based on the international ESG criteria, in the National Corporate Responsibility Index (CR Index) of the Corporate Responsibility Institute. GENESIS Pharma was the first pharmaceutical company to participate in this assessment back in 2009, and has continuously improved its performance ever since. Its ranking at the highest level of the Index, an achievement reached by only seven companies to date, reflects the company’s comprehensive strategic approach and the successful integration of sustainable development principles across its operations.